Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
J Periodontol ; 79(1): 114-22, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18166100

ABSTRACT

BACKGROUND: The purpose of this experimental study was to evaluate the collagen fiber distribution histologically after phenytoin, cyclosporin, or nifedipine therapy and to correlate it with collagen I and matrix metalloproteinase (MMP)-1 and -2 gene expression levels. METHODS: Gingival samples from the canine area were obtained from 12 male monkeys (Cebus apella). The mesial part of each sample was assessed by reverse transcription-polymerase chain reaction, whereas the distal part was processed histologically for picrosirius red and hematoxylin and eosin stainings, as well as for collagen IV immunostaining. One week after the first biopsy, the animals were assigned to three groups that received daily oral dosages of cyclosporin, phenytoin, or nifedipine for 120 days. Additional gingival samples were obtained on days 52 and 120 of treatment from two animals from each group on the opposite sides from the first biopsies. RESULTS: Picrosirius red staining showed a predominance of mature collagen fibers in the control group. Conversely, there was an enlargement of areas occupied by immature collagen fibers in all groups at days 52 and 120, which was not uniform over each section. There was a general trend to lower levels of MMP-1 gene expression on day 52 and increased levels on day 120. Phenytoin led to increased levels of MMP-2 and collagen I gene expression on day 120, whereas the opposite was observed in the nifedipine group. CONCLUSION: Cyclosporin, phenytoin, and nifedipine led to phased and drug-related gene expression patterns, resulting in impaired collagen metabolism, despite the lack of prominent clinical signs.


Subject(s)
Anticonvulsants/pharmacology , Calcium Channel Blockers/pharmacology , Collagen/drug effects , Cyclosporine/pharmacology , Enzyme Inhibitors/pharmacology , Gingiva/drug effects , Nifedipine/pharmacology , Phenytoin/pharmacology , Animals , Azo Compounds , Biopsy , Cebus , Collagen/analysis , Collagen Type I/analysis , Collagen Type I/drug effects , Collagen Type IV/analysis , Collagen Type IV/drug effects , Coloring Agents , Gene Expression Regulation, Enzymologic/drug effects , Gingiva/enzymology , Gingiva/pathology , Gingival Overgrowth/chemically induced , Gingival Overgrowth/enzymology , Gingival Overgrowth/pathology , Gingivitis/chemically induced , Gingivitis/enzymology , Gingivitis/pathology , Histocytochemistry , Male , Matrix Metalloproteinase 1/drug effects , Matrix Metalloproteinase 1/genetics , Matrix Metalloproteinase 2/drug effects , Matrix Metalloproteinase 2/genetics , Random Allocation , Reverse Transcriptase Polymerase Chain Reaction
2.
J Periodontol ; 73(11): 1313-22, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12479636

ABSTRACT

BACKGROUND: Gingival overgrowth is a common side effect following the administration of cyclosporin A (CsA). The pathogenesis of this condition is not fully understood; however, recent studies show that CsA regulates the transcription of several cytokines including transforming growth factor-beta1 (TGF-beta1). The aim of this study was to investigate the potential role of TGF-beta1 in the pathogenesis of CsA-induced gingival overgrowth, exploring a possible autocrine stimulation of TGF-beta1 as a cellular regulator of synthesis of matrix metalloproteinases (MMPs) and its tissue inhibitors (TIMPs). METHODS: Gingival fibroblasts from human normal gingiva were incubated with increasing concentrations of CsA, cultured for 24 hours, and the expression and production of TGF-beta1 determined by semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA), respectively. MMP and TIMP mRNA expression levels were also analyzed by RT-PCR. To determine the effect of TGF-beta1 on the expression of MMP and TIMP by human gingival fibroblasts under CsA treatment, human gingival fibroblast cultures were treated with sense oligonucleotides (SON) or antisense oligonucleotides (AON). RESULTS: CsA simultaneously stimulated TGF-beta1 expression and production and inhibited expression of MMP-1 and MMP-2 by human gingival fibroblasts, whereas CsA has a slight effect on TIMP-1 and TIMP-2 expression. AON reduced TGF-beta1 production as demonstrated by ELISA, whereas TGF-beta1 mRNA expression levels were not significantly modified. The inhibition of TGF-beta1 production by AON modulated MMP expression, demonstrating the autocrine inhibitory effect of TGF-beta1 in CsA-treated human gingival fibroblasts. CONCLUSIONS: The data presented here suggest that TGF-beta1 in an autocrine fashion may contribute to a reduction of proteolytic activity of human gingival fibroblasts in CsA-induced gingival overgrowth, which favors the accumulation of extracellular matrix.


Subject(s)
Cyclosporine/pharmacology , Enzyme Inhibitors/pharmacology , Gingiva/drug effects , Gingival Overgrowth/chemically induced , Gingival Overgrowth/enzymology , Matrix Metalloproteinases/biosynthesis , Transforming Growth Factor beta/physiology , Analysis of Variance , Cells, Cultured , Down-Regulation , Enzyme-Linked Immunosorbent Assay , Fibroblasts/drug effects , Fibroblasts/enzymology , Gingiva/cytology , Gingiva/enzymology , Humans , Matrix Metalloproteinase Inhibitors , Oligonucleotides, Antisense/pharmacology , Peptide Chain Initiation, Translational/drug effects , RNA, Messenger/analysis , RNA, Messenger/biosynthesis , Reverse Transcriptase Polymerase Chain Reaction , Statistics, Nonparametric , Tissue Inhibitor of Metalloproteinases/biosynthesis , Transforming Growth Factor beta/biosynthesis , Transforming Growth Factor beta/drug effects , Transforming Growth Factor beta1
3.
J Periodontal Res ; 35(1): 51-8, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10791709

ABSTRACT

Cyclosporin A (CyA) is a potent immunosuppressor used in organ transplantation and in the management of various autoimmune diseases. Gingival overgrowth is one of the side-effects of the CyA-treatment, affecting the attached gingiva of 25-81% of treated patients. To investigate the production and activity of matrix metalloproteinases (MMPs) in the CyA-induced gingival overgrowth, 2 well-documented models were utilized: the in vivo CyA-induced rat gingival overgrowth and primary cultures of human gingival fibroblasts treated with CyA. Our results obtained from the Western blot assays demonstrated clearly that the production of MMP-1 and MMP-3 was significantly inhibited by CyA at similar concentrations found in the serum of patients undergoing CyA-treatment. Moreover, the gelatinolytic activity of MMP-2 was also reduced both in cultured fibroblasts and in the rat CyA-induced gingival overgrowth. Taken together, the data presented here suggest that these inhibitory effects may contribute to the extracellular matrix (ECM) components accumulation in the CyA-induced gingival overgrowth.


Subject(s)
Cyclosporine/pharmacology , Fibroblasts/drug effects , Gingiva/drug effects , Gingival Overgrowth/chemically induced , Matrix Metalloproteinase Inhibitors , Adult , Analysis of Variance , Animals , Blotting, Western , Cells, Cultured , Electrophoresis, Polyacrylamide Gel/methods , Extracellular Matrix/enzymology , Female , Fibroblasts/enzymology , Fibroblasts/metabolism , Gingiva/cytology , Gingiva/enzymology , Gingival Overgrowth/enzymology , Humans , Male , Matrix Metalloproteinases/biosynthesis , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL